Akero Therapeutics could be a winner in the race to treat non-alcoholic steatohepatitis, a potentially life-threatening liver disease. Nash is a severe form of fatty liver disease which can cause inflammation of the liver and fibrosis, or scarring, of the liver. The disease can also lead to cirrhosis, in which the liver is permanently damaged. Individuals with Nash are part of the 20% of adults in the U.S. who have NAFLD, or non-alcoholic fatty liver disease. AKRO YTD mountain Akero Therapeutics stock.

---

Persons: steatohepatitis, Eliana Merle, Akero, Nash, NASH, Merle, NASH cirrhotics, — CNBC's Michael Bloom Organizations: U.S . Food, Drug Administration, Therapeutics Locations: U.S, Nash